Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
January 2006 Forward Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward looking statements. Such statements, based as they are on the current expectations of management of Chemokine, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Chemokine's control. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Chemokine does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, as well as other risks included in Chemokine's preliminary prospectus under the heading " risk factors", which you are urged to read. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation . These statements speak only as update of the date they are made and Chemokine is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law. 1 COMPANY AT A GLANCE • Biotechnology company with products • OTCBB: CHKT • Shares: 42 million • 52 weeks: $0.8 – 1.30 • Market Cap. $45 million • Well funded and Sufficient funds on hand for Two lead drugs to the end of Phase II trials • Also trades on Toronto: CTI 1 What are Chemokines? Chemokines are a new and explosive drug development field Evidence: 1- November 2005 Pfizer buys chemokine program of Incyte for $800 million 2- Summer 2004 Amgen buys First Chemokine company (Tularik) for $1.2 billion 3- Summer 2003 Millennium Buys Leukocytes (chemokine-based) for $600 million 3 Chemokines: New Class of Cytokines Cytokines Chemokines Epogen, Neupogen, Avonex, Intron Fusion (first chemokine-based drug). Roche/Trimeris 20B $ 1B $ Same Market Potential 4 Product Pipeline Drug Stage of Development Research Lab Testing Animal Testing Human Phase I CTCE9908 Cancer CTCE0214 Immune System Booster CTCE0324 Human Phase II Human Phase III Market Vascular Disease CTCEAnti-Infection 0422 CTCE0501 Stroke 5 Metastasisequalsdeath Product # 1: CTCE-9908 6 Cancer Relapses, due to Metastasis • Almost all cancer deaths are due to cancer metastasis • A new approach has taken by us which Stops the spread of cancer through Inhibition of cancer metastasis process 32 Cancer Relapse Due to Metastasis 2. Lung Cancer cells migrate to tissue with a high SDF-1 concentration Primary tumour 1. Cancer cells detach and migrate to blood vessel 3. Liver Cancer cells accumulate and form new tumour Bone 7 CXCR4 – A Validated Target > 2,000 publications on CXCR4 200 related to cancer CXCR4 Role established in metastasis of several types of cancer, Muller et al, Nature, 2001 Many independent labs working on CXCR4 Cancer cell 8 CTCE-9908 Targeting CXCR4 The only known natural chemokine for CXCR4 SDF-1 CXCR4 An antagonist that blocks SDF-1 binding to CXCR4, preventing the formation of metastastic tumours CTCE-9908 Cancer cell 9 CTCE-9908 Preclinical Findings Average 65% Response Rate Lung cancer 68% Bone cancer 67% Skin cancer 65% Prostate cancer 61% 12 CTCE-9908 Phase I Results No dose limiting toxicity Volunteers n = 24 (18 male, 6 female) Single dose Maximum dose tested 5 mg/kg 12 CTCE-9908 Next Step to Added Value Chemokine to start Phase Ib/II clinical trials in the Q1, 2006 Expected results in Q4, 2006 14 Bloodequalslife Product # 2: CTCE-0214 16 Blood Cell System Disorders Suppressed state (Chemotherapy, AIDS, etc.) Healthy state Bone marrow Spleen Rate of mobilization no longer fully replenishes WBCs and platelets Platelets Blood vessel Stem cells White blood cells (WBC) Fewer WBCs and platelets results in infections/fatigue and other medical complications 17 CTCE-0214 Targeting CXCR4 The only known natural chemokine for CXCR4 SDF-1 • A CXCR4 agonist • Mobilizes stem cells from bone marrow and spleen CXCR4 • Assists in the differentiation of stem cells into white blood cells and platelets CTCE-0214 Stem cells and White Blood Cells (WBC) • Mobilizes WBCs and platelets 18 CTCE-0214 Clinical Trial Phase I Conducted in Tacoma/Seattle, Washington under US-IND Enrolled 24 volunteer subjects Randomized, double-blind, placebo controlled Results: The drug showed to be safe and well tolerated Preliminary efficacy was observed 20 CTCE-0214 Clinical Phase I Efficacy 300% Increase in WBCs Safety established – No serious adverse events Dose dependant response at 6, 12 and 24 hours Warrants advancing to additional clinical trials 21 CTCE-0214 Market Potential White blood cell products represent US$3 B Projected to grow to US$4.5 B by 2008 Dominated by Neupogen® of Amgen • Takes at least 4-5 days for response on average and up to 14 days for full recovery CTCE-0214 has fast action • Potential to enhance production and infection fighting capacity of white blood cells in all patients • Potential to act synergistically with Neupogen® 22 CTCE-0214 Next Step to Value • We have started the second Phase of clinical trials Phase Ib/II in Dec. 2005 • The work is being conducted in Tacoma, Washington • Results are expected in the Summer of 2006 23 Peripheral Arterial Disease Product #3 CTCE-0324 26 Peripheral Arterial Disease (PAD) Causes: Diabetes Obesity Age Atherosclerosis Current Treatment: Amputation Physiotherapy Exercise Aspirin 10 million patients in the USA 26 Our Drug Generates New Blood Vessels Main Vasculature After 2 Weeks Control - Untreated Neovascularization occurs with CTCE-0324 compound Market Potential: $10 Billion 27 Company Management and Advisors Hassan Salari, PhD - Founder, President & CEO Founding President and CEO Inflazyme Pharma Former Professor of Medicine, UBC Walter Korz - Vice President, Drug Development Former Manager of clinical development Angiotech Malcolm Moore, D. Phil. (Medical Advisor) Professor Memorial Sloan Kettering Cancer Institute, NY Co-discoverer of Neupogen for Amgen Shahin Rafii, M.D. (Medical Advisor) Howard Hughes Medical Institute Award Recipient, Cornell Medical Center, NY Edward Ball, M.D. (Medical Advisor) Professor University of California San Diego Co-founder Medarex, NJ 30 Comparables Company Stage Market Cap. Chemokine (CHKT) Phase I/II $45 million Point Ther (POTP) Oxigene (OXGN) Phase II Phase II $100 million $115 million AnorMED (AOM) Phase II $130 million Curis (CRIS) Phase II $215 million Aastrom Bio (ASTM) Phase II $285 million Stem Cells Inc (STEM) Phase II $325 million 30 Exit Strategy (Partnership / M&A) • 2005 Pfizer and Incyte Pharmaceuticals. Incyte finishes Phase II (IBD). Pfizer license the product for $800 million • 2004 Amgen and Tularik. Tularik finishes Phase II (arthritis). Amgen buys Tularik for $1.2 Billion • 2003 Millennium Pharmaceuticals and Leukocytes. Leukocytes finishes Phase II (transplant). Millennium buys leukocyte for $600 million • Chemokine Therapeutics, 16 patents, lead in cancer, blood disorder, vascular, 9-12 months away from finishing Phase II >>>>>>>>>>> $$$ The Company in Review • Biotechnology company with 5 products – Two drugs in Phase II in 2006 – One drug entering IND in 2006 – Two products in animal studies • 16 patents • Licensing or M & A in the horizon • Publicly Traded – OTCBB: CHKT and TSX: CTI • Visit our website: www.CHKT.com 2